Cite

    Naing, A., Wang, J., Sharma, M., Sommerhalder, D., Gandhi, L., Oh, D., Jiang, Y., Michalski, J., Lee, J., Zhou, K., Taylor, N., Yan, L., Roda, J., Blum, L., Ling, L., Mikaelian, I., Depaoli, A., Hanes, V., Kaplan, D., & Lieu, H. (n.d.). 174P First-in-human study of NGM707, an ILT2/ILT4 dual antagonist antibody in advanced or metastatic solid tumors: Preliminary monotherapy dose escalation data. Immuno-oncology technology, 16, . http://access.bl.uk/ark:/81055/vdc_100172206308.0x000006